iMedix Medical Content Engine 3.13.37
Home/Drugs/DESPEC DM

DESPEC DM: Uses, Dosage & Safety Information

DESPEC DM

DESPEC DM

DESPEC DM

Dextromethorphan hydrobromide + Guaifenesin + Phenylephrine hydrochloride
Despec-DM contains guaifenesin, dextromethorphan and phenylephrine. It is marketed for cough with chest and nasal congestion. Of the three ingredients, only guaifenesin has an uncontested role: the cough suppressant works against the expectorant, and an FDA advisory committee has concluded that oral phenylephrine does not work.
  • ActiveIngredient: Dextromethorphan hydrobromide + Guaifenesin + Phenylephrine hydrochloride
  • DosageForm: Oral liquid, tablet
  • Dosage: Per package directions - strengths vary by manufacturer
  • Indications: Cough, chest congestion and nasal congestion from a cold or upper respiratory infection.
  • Manufacturer: Multiple manufacturers
  • Storage: Store at 20-25 C (68-77 F). Protect from light.
  • Drug Status: Over-the-Counter
Drug Status: Over-the-Counter
Description
Check your package
Strengths vary between manufacturers of this combination.
Read the Drug Facts panel on the pack you hold rather than relying on a general description.

What is Despec-DM?

Despec-DM is an over-the-counter cold product sold as an oral liquid or tablet, combining guaifenesin, dextromethorphan and phenylephrine. It is used for cough with chest congestion and nasal congestion from a cold. Strengths differ between manufacturers, so the Drug Facts panel on your own pack is what governs dosing.

What Each Component Does
ComponentRoleEvidence
GuaifenesinThins mucus so it clears more easilyApproved expectorant
DextromethorphanSuppresses coughApproved, but works against the expectorant
PhenylephrineIntended as a nasal decongestantFound ineffective orally by FDA advisers5

The problem sits in the middle column

Guaifenesin loosens mucus so that coughing brings it up. Dextromethorphan reduces the cough that brings it up. Putting both in one bottle is standard practice in cold remedies and has never been shown in trials to work better than either ingredient alone.

And the third ingredient may add nothing

In September 2023 an FDA advisory committee concluded that oral phenylephrine is not effective as a nasal decongestant at approved doses.5 Where a blocked nose is the main problem, pseudoephedrine from behind the pharmacy counter is the oral decongestant with demonstrated efficacy.

Compare with Bionel Pediatric, which uses the same cough ingredients with pseudoephedrine instead.

General Instructions

How to take Despec-DM

Follow the Drug Facts panel on your package. Strengths differ between manufacturers of this combination, so a general dose cannot be given reliably here.1

Drink water with it

Guaifenesin works by thinning mucus, and it does that better when you are well hydrated. Taking it with a full glass of water and drinking through the day is part of how the ingredient functions, not general advice.

Timing

Phenylephrine is stimulant-like in some people. If it disturbs sleep, move the last dose earlier in the evening.

Stop at seven days

Self-treatment beyond seven days is outside approved labelling. A cough lasting more than two weeks warrants assessment.

What to avoid

  • Any other cold or cough product – most contain at least one of these three ingredients
  • MAO inhibitors, during treatment and for 14 days after
Side Effects

Side effects

The profile combines all three components.1

Reported Side Effects
FrequencyEffectSource component
CommonNausea, vomiting, stomach upsetGuaifenesin
CommonDrowsiness, dizzinessDextromethorphan
CommonNervousness, difficulty sleepingPhenylephrine
UncommonHeadache, faster heart rate, raised blood pressurePhenylephrine
UncommonDifficulty passing urinePhenylephrine; matters in prostatic enlargement
RareRash, confusion, unsteadinessAny component
Emergency – stop and seek care
  • Chest pain, or a fast or irregular heartbeat that does not settle
  • Confusion, agitation or hallucinations
  • Inability to pass urine
  • Difficulty breathing or wheezing
  • Rash with blistering, or swelling of the face, lips or tongue
Uses

What is Despec-DM used for?

Cough with chest congestion and nasal congestion from a cold or upper respiratory infection.1

When a single ingredient is the better choice

  • Chesty cough with phlegm. Guaifenesin alone loosens mucus without suppressing the cough that clears it.
  • Dry irritating cough. Dextromethorphan alone, without an expectorant working against it.
  • Blocked nose. A decongestant with demonstrated oral efficacy rather than phenylephrine.

The honest case for the combination

Convenience. One bottle instead of two or three, one schedule to remember. That is a real benefit when several symptoms overlap – it is simply not a pharmacological one, and it comes with ingredients you may not need.

What it will not do

  • Shorten a cold. It eases symptoms while the infection runs its course, usually one to two weeks.
  • Treat a chest infection. A cough with fever beyond three days, breathlessness or coloured phlegm needs assessment.
Safety advice

Interactions Alcohol:

Use with caution
Alcohol adds to the drowsiness and unsteadiness dextromethorphan can cause, and both disturb sleep alongside the decongestant. Best avoided while taking it.

Interactions Other Medications:

Consult your doctor
MAO inhibitors are contraindicated, including for 14 days after stopping. SSRIs and triptans raise serotonin syndrome risk. Any second cold or cough product duplicates ingredients. See Interactions.

Special Groups Pregnancy:

Consult your doctor
The decongestant component is generally avoided in the first trimester and requires advice at any stage. Discuss the combination with a clinician rather than self-treating.

Special Groups Breastfeeding:

Use with caution
All three components pass into breast milk in small amounts, and the decongestant may affect milk supply. Discuss with a clinician.

Special Groups Elderly:

Use with caution
Greater sensitivity to the cardiovascular effects of the decongestant. Urinary retention in prostatic enlargement and confusion from dextromethorphan are the specific risks.

Special Groups Children:

Consult your doctor
Not for children under 4 - the FDA advises against OTC cough and cold products in this age group. Above that age, dose strictly by the package and only after considering whether medicine is needed at all.

Effects on Activities Driving:

Use with caution
Dextromethorphan can cause drowsiness and dizziness while the decongestant causes nervousness. Establish your response before driving.

Effects on Activities Operating Machinery:

Use with caution
The same applies as for driving.
Concerns

Important considerations

One ingredient cancels another

This is the central problem with the formula. Guaifenesin exists to make mucus easier to cough up; dextromethorphan exists to reduce coughing. Combination cold products have paired them for decades without trial evidence that the pairing helps, and for a chesty cough the two ingredients arguably work against each other.

And a third may do nothing

The 2023 FDA advisory committee finding on oral phenylephrine5 means the decongestant portion is of questionable value. That leaves one ingredient with an uncontested role.

Hydration is part of how it works

Guaifenesin thins secretions, and it does so more effectively when fluid intake is adequate. Taking it without drinking through the day undercuts the one component that is doing clear work.

Strengths are not standardised

Several manufacturers make this combination at differing concentrations. Carrying a dose over from another pack is a genuine risk, and it is why no figures appear in the dosage section here.

Warnings

Critical warnings

MAO inhibitors – absolute contraindication

Do not take with a monoamine oxidase inhibitor, or within 14 days of stopping one. Dextromethorphan can cause serotonin syndrome and phenylephrine a hypertensive crisis. This includes the antibiotic linezolid.1

Read your package for the dose

Strengths differ between manufacturers of this combination. Do not carry a dose over from another brand.

Cardiovascular disease

Phenylephrine is a vasoconstrictor. Do not use without advice in uncontrolled hypertension, coronary artery disease or arrhythmia.

Cough that should not be suppressed

A productive cough clears the airway. Suppressing it is appropriate for a dry irritating cough, less so where there is a lot of phlegm – which is precisely the situation the guaifenesin half is meant for.

Conditions requiring advice first

  • Asthma, chronic bronchitis or emphysema
  • Hyperthyroidism or diabetes
  • Prostatic enlargement or bladder outlet obstruction
  • Closed-angle glaucoma

Age and time limits

Not for children under 4.6 Stop after seven days.

Dosage

Despec-DM dosage

Why no figures appear here

This combination is sold by several manufacturers at differing strengths, and no single approved labelling covers all of them. Publishing a dose that does not match your pack would be worse than publishing none. Read the Drug Facts panel on the product you hold.

General limits for this class

  • Not for children under 4 – the FDA advises against OTC cough and cold products in that age group6
  • Not more than the daily maximum printed on the pack
  • Not alongside any other cough, cold or decongestant product
  • Not for more than seven days without assessment

Overdose

Excess dextromethorphan causes agitation, confusion, unsteadiness and in serious cases hallucinations. Excess phenylephrine raises blood pressure and heart rate. Overdose requires emergency assessment.

Interactions

Drug interactions

Rated on severity and documentation using the Micromedex classification.2

Significant Interactions
Interacting substanceEffect and riskSeverityDocumentation
Monoamine oxidase inhibitors – including linezolidSerotonin syndrome from dextromethorphan; hypertensive crisis from phenylephrine. Applies for 14 days after stoppingContraindicatedExcellent
Other cough, cold and decongestant productsDuplicate dosing of the same ingredients under different namesMajorExcellent
Serotonergic medicines – SSRIs, SNRIs, triptansSerotonin syndrome risk from dextromethorphanMajorGood
Antihypertensives and beta-blockersReduced blood pressure control from the decongestantModerateGood
CYP2D6 inhibitors – fluoxetine, paroxetine, bupropionIncreased dextromethorphan exposureModerateGood
Sedating antihistamines – diphenhydramine, chlorpheniramineAdditive drowsinessModerateGood
FAQs
There is no good pharmacological answer. Guaifenesin loosens mucus so coughing clears it; dextromethorphan reduces the cough. The pairing is standard in cold remedies and has never been shown in trials to work better than either ingredient alone.
That is genuinely disputed. In September 2023 an FDA advisory committee concluded that oral phenylephrine is not effective at approved doses. Products containing it remain on sale, but if congestion is your main symptom, pseudoephedrine from behind the pharmacy counter has demonstrated oral efficacy.
Because this combination is made by several manufacturers at differing strengths and no single approved labelling covers all of them. Publishing a dose that does not match your pack would be worse than publishing none.
Yes, and through the day. Guaifenesin works by thinning mucus, and it does that better when you are well hydrated. That is part of how the ingredient functions rather than general advice.
Probably not. For a productive cough, guaifenesin alone loosens the mucus without the suppressant working against it. A three-ingredient product means taking a cough suppressant and a decongestant you do not need.
Evidence and Reported Data

Evidence scope

What we know
  • Guaifenesin is an approved expectorant that thins mucus.
  • Dextromethorphan is an approved cough suppressant.
  • An FDA advisory committee concluded in September 2023 that oral phenylephrine is not effective as a nasal decongestant at approved doses.
  • The FDA advises against OTC cough and cold products in children under 4.
What remains uncertain
  • The suppressant-expectorant pairing is untested. No trial supports combining them, and their actions oppose each other for a productive cough.
  • Strengths are not standardised. No single approved labelling covers every version, which is why doses are not published here.
  • The regulatory outcome for phenylephrine is unresolved. The advisory committee finding is a recommendation, not a final rule.
  • Postmarketing reports cannot establish incidence. Spontaneous reporting has no denominator, and combination products cannot be attributed to one ingredient.

Source: 156

What has been reported to the FDA

Reporting is filed against active ingredients. FAERS has received 202,960 reports naming guaifenesin, 58,605 naming dextromethorphan and 221,392 naming phenylephrine since 2004. Data current to 30 July 2026.3

How to read this table

None of these figures can be attributed to this product. All three ingredients appear across hundreds of cold remedies, and combination products generate reports naming several drugs at once. FAERS has no denominator, so no count can become a rate.

Who was this medicine studied in?

No FDA Drug Trials Snapshot exists. Snapshots cover new molecular entities approved from January 2015 onward; all three components long predate that.

Who this is and is not appropriate for

May be considered for: adults with cough, chest congestion and a blocked nose together, who want one product rather than three, for no more than seven days.

Not appropriate for: anyone on an MAO inhibitor or within 14 days of stopping one; children under 4; uncontrolled hypertension, coronary artery disease or arrhythmia; anyone with a single symptom, for whom one ingredient does the job without the other two.

Where to go next

References

References and medical sources

  1. U.S. Food and Drug Administration. Guaifenesin, dextromethorphan hydrobromide and phenylephrine hydrochloride – OTC monograph and approved labelling. Uses, Warnings, Directions.
    Accessed 26 August 2026
    Used for: component roles, approved uses, MAOI contraindication, cardiovascular and paediatric cautions, duration limits.
    dailymed.nlm.nih.gov
  2. Micromedex. Drug interaction severity and documentation classification.
    Accessed 26 August 2026
    Used for: the two-axis severity and documentation ratings.
  3. openFDA – FAERS. Queries on generic names “guaifenesin”, “dextromethorphan” and “phenylephrine”.
    Data through 30 July 2026 – retrieved 26 August 2026
    Used for: total report counts for each component.
    open.fda.gov
  4. U.S. Food and Drug Administration, Nonprescription Drugs Advisory Committee. Meeting on oral phenylephrine efficacy, September 2023.
    Accessed 26 August 2026
    Used for: the conclusion that oral phenylephrine is not effective as a nasal decongestant at approved doses.
    fda.gov
  5. U.S. Food and Drug Administration. Use caution when giving cough and cold products to kids – consumer guidance.
    Accessed 26 August 2026
    Used for: the advice against OTC cough and cold products in children under 4.
    fda.gov

Each numbered marker links to the source supporting that specific statement.

Disclaimer

Disclaimer: The information on this page is provided for informational purposes only and is not medical advice. It does not replace professional medical consultation, diagnosis, or treatment. Do not self-medicate based on the information presented on this site. Always consult a doctor or other qualified healthcare professional before making any decisions about your health.